MAP2K7 and colorectal carcinoma: This is unusual for a MEK inhibitor in CRC, and of published preclinical studies of selumetinib and trametinib, we could only find 3 models where regression was induced as a single agent, and this was largely in cell line xenograft models [14, 26-28].